United States Patent (19) 11 Patent Number: 6,090,365 Kaminski Et Al

United States Patent (19) 11 Patent Number: 6,090,365 Kaminski Et Al

US006090365A United States Patent (19) 11 Patent Number: 6,090,365 Kaminski et al. (45) Date of Patent: *Jul.18, 2000 54 RADIOIMMUNOTHERAPY OF LYMPHOMA DeNardo et al., Pilot Studies of Radioimmunotherapy of B USING ANT-CD20 ANTIBODIES Cell Lymphoma and Leukemia Using I-131 Lym-1 Mono clonal Antibody, Antibody, Innunoconjugates, and Radiop 75 Inventors: Mark S. Kaminski, Ann Arbor, Mich.; harmaceuticals, 1 (1):17–33 (1988). Gregory M. Butchko, Miami Lakes; Grossbard, M.L., et al., Monoclonal Antibody-Based Thera Stephan D. Glenn, Davie, both of Fla.; pies of Leukemia and Lymphoma, Blood, 80 (4) :863–878 Richard L. Wahl, Ann Arbor, Mich. (Aug. 15, 1992). Anderson et al., U.S. Serial No. 07/978,891, Filed Nov. 13, 73 Assignees: Coulter Pharmaceutical, Inc., So. San 1992. Francisco, Calif.; Regents of the Anderson et al., U.S. Serial No. 08/149,099, Filed Nov. 3, University of Michigan, Ann Arbor, 1993. Mich. Badger, C.C., et al., Experimental Radioimmunotherapy with I-131-Antibody Against a Differentiation Antigen, J. * Notice: This patent issued on a continued pros Nuclear Med., 26(5):P67 (1985). ecution application filed under 37 CFR Badger, C.C., et al., Experimental Radioimmunotherapy of 1.53(d), and is subject to the twenty year Murine Lymphoma with I-Labeled Anti-T-Cell Anti patent term provisions of 35 U.S.C. bodies, Can. Res., 46:6223–6228 (1986). 154(a)(2). Buchsbaum et al., “Therapy with Unlabeled and 'I-La beled Pan-B-cell Monoclonal Antibodies in Nude Mice 21 Appl. No.: 08/972,900 Bearing Raji Burkitt's Lymphoma Xenografts”, Cancer 22 Filed: Nov. 18, 1997 Research, 52:6476–6481 (1992). Buchsbaum et al., “Improved Delivery of Radiolabeled Related U.S. Application Data Anti-B1 Monoclonal Antibody to Raji Lymphoma Xenografts by Predosing with Unlabeled Anti-B1 Mono 60 Continuation of application No. 08/639,988, Apr. 26, 1996, clonal Antibody”, Cancer Reesarch, 52:637–642 (1992). abandoned, which is a division of application No. 08/121, Czuczman et al., “A Phase 1 Dose Escalation Trial of 582, Sep. 16, 1993, Pat. No. 5,595,721. '''Labeled Monoclonal antibody OKB7 in Patients with B Cell Lymphoma', Fourth Conference on Radioimmunode tection and Radioimmunotherapy of Cancer, Abstract #55 51) Int. Cl." .......................... A61K 51/10; A61K 45/05; (Sep.1992). CO7K 16/00 DeNardo et al., “Fractionated Radioimmunotherapy of B-Cell Malignancies with ''I-Lym-1”, Cancer Research 52 U.S. Cl. .................... 424/1.49; 424/1.53; 424/144.1; (Suppl.), 50:1014s-1016s (Feb. 1990). 424/143.1; 424/154.1; 530/391.3 Eary et al., “Imaging and Treatment of B-Cell Lymphoma' Journal of Nuclear Medicine, 31(8) : 1257–1268 (Aug. 58 Field of Search .................................. 424/1.53, 1.49, 1990). 424/1441, 130.1, 131.1, 143.1, 154.1, 156.1, Eary et al., “Treatment of B-Cell Lymphoma with I-131 1741, 1.69; 530/387.2, 388.22, 391.3 Labelled Murine Monoclonal Antibodies”, Proceedings of the 35th Annual Meeting, Scientific Papers, 29(5) Abstract 56) References Cited 70 (1988). U.S. PATENT DOCUMENTS Ettinger et al., “Phase I-II Study of Isotopic Immunoglo 4.331,647 5/1982 Goldenberg .............................. 424/1.1 bulin Therapy for Primary Liver Cancer Cancer Treatment 4,361,544 11/1982 Goldenberg .............................. 424/1.1 Reports, 66(2):289-297 (Feb. 1982). 4,444,744 4/1984 Goldenberg .............................. 424/1.1 Goldenberg et al., “Targeting, Dosimetry, and Radioimmu 4,472,371 9/1984 Burchiel et al. ... 424/1.49 notherapy of B-Cell Lymphomas With Iodine-131-Labeled 4,724.213 2/1988 Epstein ......... ... 435/240.27 LL2 Monoclonal Antibody”, Journal of Clinical Oncology, 4,735,210 4/1988 Goldenberg. ... 128/654 9(4):548–564 (Apr. 1991). 4,921,690 5/1990 Beatty et al. ... ... 424/1.1 5,034.223 7/1991 Abrams et al. .. ... 424/85.8 (List continued on next page.) 5,120,525 6/1992 Goldenberg.......... ... 424/1.49 5,273.738 12/1993 Matthews et al. ... ... 424/1.49 Primary Examiner Jose G. Dees 5,595,721 1/1997 Kaminski et al. ... ... 424/1.49 Assistant Examiner Michael G. Hartley 5,736,137 4/1998 Anderson et al. ... ... 424/133.1 Attorney, Agent, or Firm-Cooley Godward LLP 5,776,456 7/1998 Anderson et al. ................... 424/133.1 57 ABSTRACT FOREIGN PATENT DOCUMENTS O 669 836 B1 9/1995 European Pat. Off.. Methods for the treatment of lymphoma by administration of WO 92/07466 5/1992 WIPO ............................ AO1N 33/20 a B cell-specific antibody are described. The invention WO 94/11026 5/1994 WIPO. encompasses providing to a patient both unlabeled antibod ies and antibodies labeled with a radioisotope. A principal OTHER PUBLICATIONS advantage of the method is that tumor responses can be Appelbaum, F.R., Radiolabeled Monoclonal Antibodies in obtained in a radiometric dose range that does not require the Treatment of Non-Hodgkin's Lymphoma, Hematology/ hematopoietic Stem cell replacement as an adjunct therapy. Oncology Clinics of North America, 5 (5):1013–1025 (Oct. 1991). 18 Claims, 7 Drawing Sheets 6,090,365 Page 2 OTHER PUBLICATIONS Order et al., “Phase I-II Study of Radiolabeled Antibody Kaminski et al., “Radioimmunotherapy of B-Cell Lym Integrated in the Treatment of Primary Hepatic Malignan phoma with ''I)Anti-B1 (Anti-CD20) Antibody”, New cies”, Int. J. Radiation Oncology Biol. Phys., 6:703–710 England Journal of Medicine, 329:459–465 (Aug. 1993). (1980). Kaminski et al., “Initial Clinical Radioimmunotherapy Parker et al., “Radioimmunotherapy of Human B-Cell Lym Results with 131-I-Anti-B1 (Anti CD20) Refractory phoma with 'Y-Conjugated Antiidiotype Monoclonal Anti B-Cell Lymphoma', Fourth Conference on Radioimmuno body”, Cancer Research, (Suppl.) 50:1022s-1028s (Feb. detection and Radioimmunotherapy of Cancer, Abstract #57 (Sep.1992). 1990). Kaminski et al., “131-I Anti-B1: Initial Clinical Evaluation Press et al., “Treatment of Refractory Non-Hodgkin's Lym in B-Cell Lymphoma', Third Conference On Radioimmu phoma With Radiolabeled MB-1 (Anti-CD37) Antibody", nodetection and Radioimmunotherapy of Cancer, Abstract Journal of Clinical Oncology, 7(8): 1027-1038 (Aug. 1989). No. 144 (Nov. 1990). Letvin et al., “Use of Radiolabeled Monoclonal Anti-B1 Press et sl., “Monoclonal Antibody IF5 (Anti-CD20) Sero Antibody for B Lymphocyte Imaging in Rhesus Monkeys”, therapy of Human B Cell Lymphomas’, Blood, 69:584-591 Nucl. Med. Biol., 14(2):99-105 (1987). (1987). Macklis et al., “Induction of Programmed Cell Death in Press et al., “Radiolabeled Antibody (RAb) Therapy of Malignant Lymphomas After Radioimmunotherapy”, Relapsed B Cell Lymphomas', Lymphom, Abstract #1077 Fourth Conference on Radioimmunodetection and Radio (Apr. 1992). immunotherapy of Cancer, Abstract #39 (Sep. 1992). Macklis et al., “Cell Cycle Alterations, Apoptosis, and Stashenko et al., “Characterization of a Human B Lympho Response to Low-Dose-Rate Radioimmunotherapy in Lym cyte-Specific Antigen”, Journal of Immunology, 125(4) phoma Cells' Int. J. Radiation Oncology Biol. PhyS., :1678–1685 (Oct. 1980). 27:643-650 (1993). Macklis et al., “Radiobiologic Basis of Lymphoma Weinstein et al., “Monoclonal Antibodies in the Lymphatics: Radio-Immunotherapy”, Radiation Oncology Biol. Phys., Toward the Diagnosis and Therapy of Tumor Metastases”, vol. 24, Supplement 1, p. 184, Abstract #101 (1992). Science, 218:1334–1337 (Dec. 1982). Order, "Monoclonal Antibodies: Potential Role in Radiation “Immunomedics Reports on Lymphoma Imaging and Therapy and Oncology”, Int. J. Radiation Oncology Biol. Therapy Progress at Cancer Conference”, New Jersey, Can Phys., 8(7): 1193–1201 (1982). cer Research Weekly (1993). U.S. Patent Jul.18, 2000 Sheet 1 of 7 6,090,365 A U.S. Patent Jul.18, 2000 Sheet 2 of 7 6,090,365 U.S. Patent Jul.18, 2000 Sheet 3 of 7 6,090,365 FG.2A U.S. Patent Jul.18, 2000 Sheet 4 of 7 6,090,365 FG.2C U.S. Patent Jul.18, 2000 Sheet 5 of 7 6,090,365 FG. 3A COOH O2N NH2 p-NO2-Phe STEP HC MeOH O 2 OCH3C NH2HCI me-p-NO2-Phe STEP 2 TEACH3 H2N NH2 O H(CH3) H3(H) - O2N NH NH2 NH2 p-NO2-Bz-2-oxo-methyl-diethylenetriomine STEP3 BHTHF HC H(CH3) CH3(H) /-Q O2 N NH NH 2 -3HC NH2 p-NO2-BZ-methyl-diethylenetriomine STEP4 Br KOH ( COOH U.S. Patent Jul.18, 2000 Sheet 6 of 7 6,090,365 FG. 3B H(CH3) CH3(H) on-Y)- NCOOH COOH} COOH COOH COOH p-NO2-Bz- methyl-DTPA H2 STEP 5 PC/C pHIO H(CH3) CH3(H) N go Y N 1 o COOH COOH COOH p-NH2-Bz-methyl-DTPA S STEP 6 /V C Cl pH 8.5 H(CH3) CH3(H) so-YY(c. COOH COOH> COOH OOH OOH p-SCN-BZ- methyl-DTPA U.S. Patent Jul.18, 2000 Sheet 7 of 7 6,090,365 (6IQO)Þ8 (OZOO)|8 (2200)28§§ qÔI 28(IZOO) 6,090,365 1 2 RADIOMMUNOTHERAPY OF LYMPHOMA In light of these findings, it is worth considering whether USING ANT-CD20 ANTIBODIES leSS restricted antigens on lymphoid tumor cells might be appropriate targets for therapy. In general, anti-tumor effects CROSS REFERENCE TO RELATED of antibodies against Such antigens have only been modest. APPLICATIONS Patients with chronic lymphocytic leukemia (CLL) and cutaneous T-cell lymphomas, for instance, have been treated This application is a Continuation of U.S. application Ser. with the T101 antibody which binds a 65 Kd glycoprotein No. 08/639,988, filed Apr. 26, 1996, now abandoned, which present on malignant and Some normal T-cells (7). Transient is a Divisional of application Ser. No. 08/121,582, filed Sep.

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    34 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us